RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
New Zoonoses Report out now: avian flu most notable outbreak in 2022 Throughout 2022, the Netherlands faced a persistent avian flu outbreak, affecting 76 poultry farms. The virus also infected numerous wild birds and various wild mammals. These findings are presented in the Zoonoses Report, an annual publication issued jointly by RIVM and the Netherlands Food and Consumer Product Safety Authority (NVWA).
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
COVID-19 vaccination for risk groups: over-60s, flu vaccine group, care workers and pregnant women From 19 September 2023 on, the first people will receive an invitation for COVID-19 vaccination. The first invitations will be sent by RIVM to people aged 60 years and older.
Gastrointestinal symptoms on the rise, but still fewer than before the COVID-19 pandemic In 2022, the number of enteric infections – which mainly cause gastrointestinal symptoms – was higher than it was in the previous two years. However, the total number of infections was still lower than before the coronavirus pandemic.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
COVID-19 vaccine uptake related to neighbourhood demographics COVID-19 vaccine uptake was lower in neighbourhoods that had proportionately higher percentages of residents from a non-Western migration background and residents who were more likely to vote for right-wing Christian and right-wing conservative political parties. iStock